home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630237.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
3KB
|
52 lines
Document 0237
DOCN M9630237
TI Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent
inhibitor of HIV-1 replication.
DT 9603
AU Angel JB; Saget BM; Walsh SP; Greten TF; Dinarello CA; Skolnik PR;
Endres S; Department of Medicine, Tufts University School of Medicine,;
Boston, Massachusetts, USA.
SO AIDS. 1995 Oct;9(10):1137-44. Unique Identifier : AIDSLINE MED/96098129
AB OBJECTIVE: To determine the effects of rolipram, a specific type IV
phosphodiesterase inhibitor, on tumor necrosis factor (TNF)-alpha
production and HIV-1 replication. DESIGN: TNF-alpha enhances HIV-1
replication in vitro; blocking TNF-alpha and thereby inhibiting HIV-1
replication may therefore potentially delay progression of HIV disease.
Pentoxifylline is a non-specific phosphodiesterase inhibitor that blocks
TNF-alpha synthesis and HIV-1 replication in vitro and has been shown in
preliminary clinical studies to decrease viral replication in
HIV-1-infected patients. Rolipram, which selectively inhibits the
predominant phosphodiesterase isoenzyme of monocytes, inhibits
lipopolysaccharide (LPS)-induced TNF-alpha with 500-fold greater potency
than pentoxifylline. We, therefore, hypothesized that rolipram would be
a powerful inhibitor of HIV-1 replication. METHODS: The effects of
rolipram and pentoxifylline on TNF-alpha production and HIV-1
replication were determined in infected and uninfected peripheral blood
mononuclear cells (PBMC), in a chronically infected promonocytic cell
line (U1) and in an acutely infected monocytic cell line (BT4A3.5).
TNF-alpha was determined by specific radioimmunoassay and HIV-1
replication was measured by p24 antigen and HIV-1 mRNA production.
RESULTS: Rolipram inhibited TNF-alpha production in LPS- and phorbol
myristate acetate (PMA)-stimulated PBMC and in PMA-stimulated U1 cells.
Rolipram also inhibited HIV-1 replication in the U1 cell line, as well
as in acutely infected PBMC and BT4A3.5 cells. Depending on the
experimental conditions, rolipram was 10-600 times more potent, on a
molar basis, than pentoxifylline. CONCLUSION: Rolipram is a potent
inhibitor HIV-1 replication and therefore deserves further investigation
as a potential therapeutic agent in the treatment of HIV-1-infected
patients.
DE Cell Line Cells, Cultured Comparative Study Human HIV Core Protein
p24/BIOSYNTHESIS HIV-1/DRUG EFFECTS/*PHYSIOLOGY Leukocytes,
Mononuclear/DRUG EFFECTS/METABOLISM/VIROLOGY
Lipopolysaccharides/PHARMACOLOGY Monocytes/DRUG
EFFECTS/METABOLISM/VIROLOGY Pentoxifylline/PHARMACOLOGY
Phosphodiesterase Inhibitors/*PHARMACOLOGY Pyrrolidinones/*PHARMACOLOGY
RNA, Viral/BIOSYNTHESIS Support, U.S. Gov't, P.H.S.
Tetradecanoylphorbol Acetate/PHARMACOLOGY Tumor Necrosis
Factor/*ANTAGONISTS & INHIB/BIOSYNTHESIS Virus Replication/*DRUG
EFFECTS JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).